Boehringer Ingelheim acquires GST to expand stem cell capabilities

By Nikita Chaurasia  Date: 2020-07-29

Boehringer Ingelheim acquires GST to expand stem cell capabilities

Boehringer Ingelheim, a leader in pharmaceutical products, has recently made it to the headlines by acquiring Belgium-based veterinary biotech firm, Global Stem cell Technology (GST).

According to reliable sources, the collaboration with GST will allow Boehringer to expand its development pipeline, while parallelly focusing on setting higher standards of animal healthcare. However, the financial details of the deal were not disclosed.

The two companies had initially partnered in the year 2018 and had launched a stem cell product, Arti-Cell® Forte in 2019.  Arti-Cell® Forte is apparently the first stem cell product which was granted marketing authorization by the European commission in the veterinary domain.

Boehringer Ingelheim Animal Health’s Head of Global Strategic Marketing Jean-Luc Michel, was reported stating that the company had finally decided to acquire GST after two years of partnership which will help in expanding Boehringer Ingelheim’s portfolio. He added that GST’s expertise in stem cell production will allow Boehringer to  deliver advanced and innovative solutions to their clients.

Jan Spaas CEO of GST mentioned that that Boehringer Ingelheim’s mission to lead a new wave of development and innovation in the veterinary industry complies with GST vision. He further claimed that GST will operate as a new research and development division Boehringer’s banner.

For those uninitiated, Boehringer Ingelheim Animal Health is one of the largest animal health businesses in the world, with net sales of 4 billion euros in 2019 and presence in more than 150 countries.

On the other hand, Global Stem cell Technology (GST) is a biotech company with primary focus on R&D activities and manufacture of veterinary stem cell-based products.

In other news, Boehringer Ingelheim had recently teamed up with Biognosys to enhance next-gen proteomics applications for drug development and discovery.

Source credits: https://www.boehringer-ingelheim.com/press-release/boehringer-ingelheim-acquires-global-stem-cell-technology

https://www.news-medical.net/news/20200724/Boehringer-Ingelheim-and-Biognosys-join-forces-on-applying-quantitative-proteomics-tools-in-drug-discovery.aspx

About Author

Nikita Chaurasia     aeresearch.net

Nikita Chaurasia

An accomplished professional in the field of content development, playing with words comes naturally to Nikita Chaurasia. After completing her post-graduate MBA degree in Advertising and PR, Nikita worked across numerous content-driven verticals, undertaking diverse r...

Read More

More News By Nikita Chaurasia

Motorola Solutions to offer Norwegian Health Emergency Service with CRS

Motorola Solutions to offer Norwegian Health Emergency Service with CRS

By Nikita Chaurasia

Motorola Solutions has announced to have been selected by Helsetjenestens Driftsorganisasjon for Nødnett HF (HDO HF) to offer the Norwegian Health Emergency Service with a new CRS (Command Central Control Room Solution). Confirming the news,&...

Nestle India exploring options to directly sell products to consumers

Nestle India exploring options to directly sell products to consumers

By Nikita Chaurasia

Nestle India Ltd. is reportedly exploring their options of trying their hands at direct selling since consumers are largely turning towards the internet to purchase products ranging from staples to medicines amidst the COVID-19 pandemic. While the n...

Razorpay: New funding en route, meteoric rise in market value expected

Razorpay: New funding en route, meteoric rise in market value expected

By Nikita Chaurasia

Indian startup Razorpay is reportedly in discussions with Singapore-based sovereign wealth fund GIC Pvt. Ltd. and other existing investors to raise around USD 200 million in a funding round that would allow the fintech company to double its valuation...

FDA to allow pharma companies modify COVID-19 shots amid variants surge

FDA to allow pharma companies modify COVID-19 shots amid variants surge

By Nikita Chaurasia

With the rising cases of Coronavirus variants, the United States Food & Drug Administration (FDA) has reportedly introduced guidelines for pharmaceutical companies to modify their COVID-19 vaccine doses in an effort to curb the spread of the dise...

Gan & Lee partners with IDF to expand its diabetes treatment portfolio

Gan & Lee partners with IDF to expand its diabetes treatment portfolio

By Nikita Chaurasia

China-based leading pharmaceutical organization Gan & Lee Pharmaceuticals Co. Ltd. has announced to have signed a strategic collaboration with the International Diabetes Federation (IDF) to bolster its efforts towards promoting the prevention and...